Articles tagged with Cancer Genomics
Researchers from Carnegie Mellon University have developed a new approach to bridge the gap between available data and actionable insight in medicine. They introduced contextualized modeling, a family of ultra-personalized machine learning methods, to build individualized gene network models for nearly 8,000 tumors across 25 cancer typ...
A new study found that childhood cancer survivors' genetics and therapy type play a significant role in determining their risk of developing a second cancer. Radiation exposure was the most significant contributor to secondary cancer risk, accounting for about 40% or more of the risk.
A new AI tool developed by University of Missouri researchers can predict the 3D shape of chromosomes inside individual cells, providing a new view of how genes work. The tool helps identify unique differences in chromosome folding between cells, which controls gene activity and can lead to diseases like cancer.
A study published in Genome Medicine has identified the underlying predisposition for Wilms' tumors, highlighting the role of mutations in tumor suppressor genes like WT1. The research also reveals a significant proportion of childhood kidney tumors have a hereditary component, with implications for genetic counseling and monitoring.
Charles G. Mullighan, a leading leukemia researcher at St. Jude Children's Research Hospital, has been elected Fellow of the Royal Society. His work on genomic research has advanced the understanding and treatment of acute leukemia in children.
A study published in Nature Communications has discovered two genetic variants linked to breast cancer in black South African women, shedding light on the genetic basis of this disease in African populations. The findings have implications for developing targeted treatments and improving cancer risk prediction tools.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
Researchers identify colibactin, a bacterial toxin that alters DNA, as a potential trigger for early-onset colorectal cancer. Exposure to colibactin in childhood may imprint a distinct genetic signature on colon cells, increasing the risk of developing cancer before age 50.
Scientists at St. Jude Children's Research Hospital discovered FOXR2 activation in multiple pediatric CNS tumor types, including high-grade gliomas and pineoblastomas, with significantly different clinical outcomes. The study highlights the importance of combining molecular findings with other diagnostic approaches to improve treatment...
Combining AI with traditional mathematical modeling can improve cancer treatment outcomes by providing specificity and accuracy. The researchers emphasize the importance of ethically sharing health data to create reproducible science, protecting patient privacy while promoting scientific integrity.
Researchers developed a cell-based reporter assay that can quantify epigenetic changes induced by chemicals and potential carcinogens. The epi-TK assay detects gene silencing and activation, reflecting epigenetic changes associated with both gene expression and DNA methylation.
Cells dynamically adjust nuclear pore complexes like a retail store opening more checkout lines to regulate genome access. Research findings suggest that protein creation and disposal systems control the amount of NPCs in cells.
Dr. Bing Ren, a renowned expert in genomics and epigenetics, joins the New York Genome Center as its new scientific director and CEO. His groundbreaking contributions will focus on translating genomic research into actionable insights for improving human health.
New research reveals aldosterone-producing adenomas harbor at least four distinct cell types, including cortisol-producing cells that contribute to unexpected health issues. The study also identifies potential role of lipid-associated macrophages in influencing hormone production and tumor growth.
A new review led by Moffitt Cancer Center researchers shows that genomic tests can provide more detailed information about prostate cancer. However, experts highlight the need for more data on the cost-effectiveness and clinical utility of these tests, as well as their impact on racial and ethnic groups.
A new study has mapped genetic differences across children with Wilms tumour, a type of childhood kidney cancer, to understand how it develops and responds to treatment. The research suggests that inherited genetic changes predetermine tumour development, growth, and response to treatments.
Researchers explore HER2-low breast cancer, a new clinical subtype that benefits from novel treatments and personalized care. Current testing methods are not always accurate, calling for better detection methods to correctly identify patients who can benefit from these new therapies.
BGI Genomics has launched a National Cervical Cancer Prevention and Control Program in Brunei, utilizing HPV DNA testing for large-scale screening. The initiative aims to increase accurate and reliable early detection methods, aligning with the WHO's global strategy of cervical cancer elimination by 2030.
A new study reveals unexpected patterns of mutation inheritance in family trees of single cells, showing that some DNA damage can last for two to three years without repair. This persistence creates multiple chances for harmful mutations to occur, leading to cancer development.
Researchers developed a system to monitor tumor-informed circulating tumor DNA (ctDNA) after comprehensive genomic profiling (CGP), enabling accurate prediction of patient outcomes. The study showed that this approach can be effectively used in conjunction with CGP data to predict cancer relapse and treatment response, improving person...
A study by Tulane University researchers found that tumors in female fruit flies grew 2.5 times larger than those in male fruit flies due to sex-based differences in immune response. The stronger innate immune response in females accelerated tumor growth.
Children's Hospital of Philadelphia researchers discovered a gene signature that identifies patients with T-ALL at high risk of relapse. The study found a potential therapeutic treatment, venetoclax, which targets specific cells associated with poor outcomes.
MSK researchers have identified a compound that selectively kills glioblastoma cells while sparing healthy cells. They also developed a new method to study cancer evolution by introducing mutations in specific genes, allowing for the rapid regression of leukemia and understanding its behavior.
The Clinical Genome Resource (ClinGen) has published data on over 2,700 genes curated for clinical relevance to genetic diseases. The consortium has identified 2,420 gene-disease relationships, classified 5,161 unique pathogenic variants and validated 1,557 genes for dosage sensitivity assessments.
A team of researchers has identified the USP50 protein's role in regulating DNA replication by deciding which enzymes to use during critical processes. The study found that USP50 helps cells balance nuclease and helicase activity, preventing replication defects when it is absent.
A new analytical tool called PATH can quantify tumor cell plasticity, which is a key characteristic of cancer that leads to treatment resistance and metastatic spread. Researchers used PATH to analyze tumor samples from animal models and human patients, revealing new details of how tumors exploit plasticity to spread.
A new study has identified NSD2 as a fundamental factor in early stages of prostate cancer development, found to alter androgen receptor function leading to rapid cell division and growth. The study may suggest a new way to therapeutically target prostate cancer by targeting the epigenetic component NSD2.
Scientists have discovered over 50,000 unusual DNA structures called i-motifs in the human genome, which are concentrated in key functional areas and may play a role in regulating gene activity. This finding offers new possibilities for diagnostic and therapeutic approaches to diseases such as cancer.
Researchers studied three polyploid plant species that successfully adapted to extra DNA and found distinct molecular solutions. The study identified the CENP-E molecule as a promising target for killing polyploid cancers. Additionally, 'meiosis genes' were found to play a crucial role in rapid adaptation to polyploidy.
The study identified 96 mutated driver genes, 9 of which were previously unknown in CRC, and 24 that were new to any form of cancer. A new molecular classifier system was developed, identifying five distinct CRC prognostic subtypes with unique molecular characteristics.
Researchers discovered novel genetic variations that influence relapse risk in children with standard-risk B-cell acute lymphoblastic leukemia (SR B-ALL). The study highlights the importance of genomic profiling in accurately determining patient risk and tailoring treatment intensity.
Researchers at the University of Bologna have identified a specific location and genomic context where DNA breaks occur due to topoisomerase I inhibition. This discovery could lead to new cancer treatments by inducing DNA damage and genomic instability in cancer cells.
Researchers predict that circular RNAs will play a crucial role in cancer diagnosis and treatment, enabling innovative diagnostic and therapeutic developments. The study highlights the potential of circRNAs as biomarkers, therapy targets, and even immune response inducers against cancer cells.
Researchers developed a novel liquid biopsy technique to monitor disease evolution in metastatic prostate cancer patients. The method analyzes DNA and RNA in circulating extracellular vesicles, capturing tumor genomics and transcriptomic changes.
Researchers found that bowel cancer cells can regulate their growth using genetic on-off switches, allowing them to maximize survival chances. The study also showed that DNA repair genes can be repeatedly created and repaired, acting as 'genetic switches' to control tumour growth or put the brakes back on.
A new editorial paper discusses molecular and cytogenetic analyses used to identify distinct subtypes of acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS). Researchers found that around 15% of AML cases remain genetically unclassifiable, emphasizing the need for further research.
A new genomic test has improved clinical care for some children with cancer in England by informing individual patient care. The study found that the test provided additional insights that improved care for 20 children and reduced the number of tests required.
A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.
A new, streamlined urine DNA test detects primary bladder cancer more accurately than current methods, potentially reducing the need for invasive cystoscopy. The test shows high sensitivity and specificity, even for detecting high-grade noninvasive papillary carcinoma.
A new machine-learning model using serum fusion-gene levels predicts HCC with an accuracy of 83-91%, significantly improving upon current biomarkers like serum alpha-fetal protein. This breakthrough tool may help identify patients at risk and monitor cancer recurrence, leading to improved survival rates.
The Kids First DRC has introduced an upgraded data portal to streamline big data search and analysis, improving collaborative pediatric research outcomes. The new portal integrates diverse datasets, including genomic information from the Children's Brain Tumor Network, to foster cross-disciplinary research.
A comprehensive molecular portrait of KRAS has been established, revealing its key role in pancreatic cancer progression and resistance to treatment. The study identifies ERK as a critical regulator of KRAS activity, with implications for developing targeted therapies.
A genomic study of over 5,000 veterans with advanced prostate cancer reveals significant differences in frequencies of alterations associated with race and ethnicity. Alterations in immunotherapy targets were more common in Black veterans, potentially leading to opportunities for precision-based therapy.
A new study found that PARP1 is involved in the repair of telomeres, which can lead to genomic instability and cancer. Impairing this process can lead to telomere shortening and increased risk of cancer. The findings challenge existing dogma and open up new possibilities for improving cancer therapies.
Researchers at Johns Hopkins Medicine have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells. The findings reveal what goes wrong when a group of molecules and enzymes trigger the cell cycle, leading to cancer development.
Researchers have developed a new urine-based test that identifies high-grade prostate cancer by analyzing 18 genes linked to the disease. The test, called MyProstateScore2.0, was shown to be nearly 100% correct at ruling out aggressive cancers and helped avoid up to 41% of unnecessary biopsies.
Two new Review articles explore AI's application in early cancer detection, highlighting its potential to enhance diagnostic accuracy and improve treatment selection. The articles emphasize the need for a robust, multi-disciplinary approach to integrate AI into medicine.
Researchers identified a small set of proteins governing anaplastic large cell lymphoma (ALCL) identity and found that drugs targeting the STAT family of proteins already exist for treatment. The study provides insight into potential vulnerabilities in ALCL cells.
A KAIST-Seoul National University Hospital research team has developed a computational workflow that predicts metabolites and metabolic pathways associated with somatic mutations in cancers. The workflow uses genome-scale metabolic models and mutation data to identify altered metabolic pathways that contribute to cancer progression.
Researchers linked red/processed meat consumption to increased colorectal cancer risk, highlighting two genetic markers (HAS2 and SMAD7) that alter cancer risk levels based on meat intake. The study analyzed data from nearly 70,000 people and found a 30-40% increased risk for those with high red or processed meat intake.
A long non-coding RNA called lncREST has been identified as a crucial component of the stress response during DNA replication. Its absence leads to impaired stress signalling, resulting in severe DNA defects and cell death. The discovery opens up new avenues for developing anti-tumour therapies.
The NCI-MATCH precision medicine trial discovered that trastuzumab-pertuzumab, approved for HER2-positive breast cancer, can shrink tumors in patients with other types of cancer and high levels of the HER2 gene. The study found a 12% confirmed overall response rate, with partial responses in various cancers.
A recent study has uncovered 145 genes crucial for genome stability, shedding light on genetic factors influencing human health over a lifespan. The research highlights the potential of SIRT inhibitors as a therapeutic pathway for cohesinopathies and other genomic disorders.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
Researchers developed a molecular predictor of radiation response using cell line data and machine learning-based approaches, capturing a wider range of biological processes. The new gene signature has the potential to aid decision-making, personalize treatments, and improve outcomes for various types of cancers.
The study classifies pediatric acute myeloid leukemia (pAML) into 23 distinct molecular categories, revealing unique biological characteristics and drivers of the disease. This classification provides a path forward for clinicians to identify distinct pAML sub-types and guide treatment decisions.
Studies at single-cell resolution reveal significant tumor cell heterogeneity and an immune-evasive environment that contributes to treatment resistance in T follicular helper cell lymphomas. A novel marker, PLS3, is also identified as a key player in this process.
A study by the University of the Basque Country uses game theory to establish that tumours with less cellular heterogeneity are more aggressive. The work suggests a fresh theoretical approach for new therapeutic strategies, focusing on preserving high intratumour heterogeneity.
Research reveals chromatin's role in preventing DNA-RNA hybrid formation, which causes genomic instability and cancer. DNA-RNA hybrids are a risk factor in tumour development, suggesting potential use as an indicator of carcinogenic risk.